Literature DB >> 14644021

Status and future direction of male contraceptive development.

C Richard Lyttle1, Gregory S Kopf.   

Abstract

Control of fertility constitutes a global health issue, as overpopulation and unintended pregnancy have both major personal and societal impact. Although the contraceptive revolution in the 1960s following the development of hormonal-based oral contraceptives for women has had a major impact on societal dynamics in several cultures, little product innovation has occurred since then. One solution to this global health issue lies in the development of new and innovative contraceptives for both women and men, the goal of which is to provide a range of options for people at all stages and walks of life. Currently, three options for male-based contraception exist (i.e. withdrawal, condoms and vasectomy), and these are acknowledged as woefully inadequate. Introduction of new forms of male contraception based on both hormonal and non-hormonal paradigms are wanted and needed; this need is now becoming recognized by both the public and private sectors. New and innovative products will come from our knowledge of the unique physiology and genetics of reproduction, as well as by exploiting existing and future genomics, proteomics and protein network platforms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14644021     DOI: 10.1016/j.coph.2003.07.002

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  2 in total

1.  Reversibility of Vasalgel™ male contraceptive in a rabbit model.

Authors:  Donald Waller; David Bolick; Elaine Lissner; Christopher Premanandan; Gary Gamerman
Journal:  Basic Clin Androl       Date:  2017-04-05

2.  Investigation in vitro Expression of CatSper Sub Fragment followed by Production of Polyclonal Antibody: Potential Candidate for The Next Generation of Non Hormonal Contraceptive.

Authors:  Mahboobeh Nazari; Manouchehr Mirshahi; Seyed-Javad Mowla; Taravat Bamdad; Sina Sarikhani
Journal:  Cell J       Date:  2012-12-12       Impact factor: 2.479

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.